Shopping Cart

Your shopping cart is currently empty

Amisulpride

Name: Amisulpride
Brand: TargetMol
SKU: T0811
Price: 39 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T0811Cas No. 71675-85-9

Alias DAN 2163

Amisulpride (DAN 2163) (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.

Amisulpride

Copy Product Info

🥰Excellent

Purity: 99.99%

Catalog No. T0811Alias DAN 2163Cas No. 71675-85-9

Pack Size	Price	USA Warehouse	Global Warehouse
25 mg	$42	In Stock	In Stock
50 mg	$58	In Stock	In Stock
100 mg	$79	In Stock	In Stock
200 mg	$138	In Stock	In Stock
500 mg	$251	In Stock	In Stock
1 g	$372	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$39	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.99%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Amisulpride AI Summary

Amisulpride exhibits a diverse range of bioactivities, including significant interactions with various human receptors and enzymes. It has high affinity for the human dopamine D2 (Ki = 12.59 nM) and D3 receptors (Ki = 3.981 nM), as well as the 5HT2B (Ki = 316.23 nM), 5HT2A (Ki = 630.96 nM), and 5HT7 receptors (Ki = 25.12 nM). The compound also shows affinity for the adrenergic alpha-2 receptor in rat cerebral cortex (Ki = 125.89 nM). Additionally, it exhibits potent antagonistic activity at the D2 receptor in CHOK1 cells co-expressing G-alpha 15, with an IC50 of 3.04 nM. In terms of pharmacokinetics, Amisulpride demonstrates good bioavailability (fraction absorbed, Fa = 1.0) and a high fraction unbound in human plasma (Fu = 0.84). Its total body clearance (CL) is 7.8 mL.min-1.kg-1, with renal clearance (CL_renal) of 4.4 mL.min-1.kg-1 and a moderate volume of distribution at steady state (Vdss = 5.8 L.kg-1). The compound is highly soluble in 0.1 M phosphate buffer (600 µM at pH 7.4) and exhibits a strong solubility exceeding 500,000 nM. Amisulpride has been identified to inhibit several enzymes and pathways, including Bacillus subtilis Sfp phosphopantetheinyl transferase, human lipoxygenase (15-hLO), Histone Lysine Methyltransferase G9a, ERK signaling, and Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1). Furthermore, it shows antiviral activity against SARS-CoV-2, inhibiting virus-induced cytotoxicity and the 3CL-Pro protease, as well as demonstrating effects on VERO-6 and HRCE cells. In antimicrobial assays, Amisulpride displays inhibitory activity against several bacterial and fungal pathogens, including moderate inhibition of Pseudomonas aeruginosa and Staphylococcus aureus MRSA, and antifungal activity against Candida albicans. The compound shows minimal hepatotoxicity with low incidences of liver toxicity and specific bioactivity against transport proteins such as BSEP, MRP2, MRP3, and MRP4. It further exhibits inhibitory activity against human HDAC6 and SET7, as measured by enzymatic assays. Overall, Amisulpride's broad spectrum of bioactivities and favorable pharmacokinetic properties suggest its potential utility in diverse therapeutic applications..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Amisulpride (DAN 2163) (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.
Targets&IC50	D3 receptor:3.2 nM (Ki), D2 receptor:2.8 nM (Ki)
Synonyms	DAN 2163

Chemical Properties

Molecular Weight	369.48
Formula	C₁₇H₂₇N₃O₄S
Cas No.	71675-85-9
Smiles	C(NCC1N(CC)CCC1)(=O)C2=C(OC)C=C(N)C(S(CC)(=O)=O)=C2
Relative Density.	1.2 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 65 mg/mL (175.92 mM), Sonication is recommended.

H2O: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 50 mg/mL (135.33 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.41 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO/Ethanol

	1mg	5mg	10mg	50mg
1 mM	2.7065 mL	13.5325 mL	27.0651 mL	135.3253 mL
5 mM	0.5413 mL	2.7065 mL	5.4130 mL	27.0651 mL
10 mM	0.2707 mL	1.3533 mL	2.7065 mL	13.5325 mL
20 mM	0.1353 mL	0.6766 mL	1.3533 mL	6.7663 mL
50 mM	0.0541 mL	0.2707 mL	0.5413 mL	2.7065 mL
100 mM	0.0271 mL	0.1353 mL	0.2707 mL	1.3533 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc